Luye Pharma Group (HK:2186) has released an update.
Luye Pharma Group Ltd. announced that their drug LY03010, aimed at treating schizophrenia and schizoaffective disorder, has passed the U.S. FDA’s Pre-Approval Inspection with no objections, a significant step towards the drug’s approval. This achievement underscores the company’s adherence to high international manufacturing standards and paves the way for potential commercialization in the U.S. market, where the drug could offer new treatment options for patients.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
